Literature DB >> 7926813

Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver.

F L Chartier1, J P Bossu, V Laudet, J C Fruchart, B Laine.   

Abstract

Hepatocyte nuclear factor 4 (HNF-4) is a key transcription factor involved in the specific expression of many genes in liver and intestine. Sequences of cDNAs coding for HNF-4 have been established in rat and Drosophila melanogaster. Rat HNF-4 exhibits two isoforms which probably result from differential splicing. We have isolated HNF-4 cDNAs from an adult human cDNA library. Sequence analysis revealed that two HNF-4 isoforms are also present in human liver. The complete sequence of the longest human isoform has been established and compared to the rat HNF-4 amino-acid sequences.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7926813     DOI： 10.1016/0378-1119(94)90079-5

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  29 in total

1.  Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1.

Authors:  F M Sladek; M D Ruse; L Nepomuceno; S M Huang; M R Stallcup
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  The activity of the activation function 2 of the human hepatocyte nuclear factor 4 (HNF-4alpha) is differently modulated by F domains from various origins.

Authors:  L Suaud; P Formstecher; B Laine
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 3.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

4.  Assessing self-renewal and differentiation in human embryonic stem cell lines.

Authors:  Jingli Cai; Jia Chen; Ying Liu; Takumi Miura; Yongquan Luo; Jeanne F Loring; William J Freed; Mahendra S Rao; Xianmin Zeng
Journal:  Stem Cells       Date:  2005-11-17       Impact factor: 6.277

Review 5.  The orphan nuclear receptors at their 25-year reunion.

Authors:  Shannon E Mullican; Joanna R Dispirito; Mitchell A Lazar
Journal:  J Mol Endocrinol       Date:  2013-11-26       Impact factor: 5.098

Review 6.  Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Mol Cancer Ther       Date:  2010-11-01       Impact factor: 6.261

7.  Characterization of a dominant negative mutant form of the HNF-4 orphan receptor.

Authors:  D G Taylor; S Haubenwallner; T Leff
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

Review 8.  Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review.

Authors:  Asfar S Azmi; Ginny W Bao; Jiankun Gao; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Curr Drug Discov Technol       Date:  2013-06

9.  Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes.

Authors:  Jason Flannick; Nicola L Beer; Alexander G Bick; Vineeta Agarwala; Janne Molnes; Namrata Gupta; Noël P Burtt; Jose C Florez; James B Meigs; Herman Taylor; Valeriya Lyssenko; Henrik Irgens; Ervin Fox; Frank Burslem; Stefan Johansson; M Julia Brosnan; Jeff K Trimmer; Christopher Newton-Cheh; Tiinamaija Tuomi; Anders Molven; James G Wilson; Christopher J O'Donnell; Sekar Kathiresan; Joel N Hirschhorn; Pål R Njølstad; Tim Rolph; J G Seidman; Stacey Gabriel; David R Cox; Christine E Seidman; Leif Groop; David Altshuler
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

10.  Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes.

Authors:  T Drewes; S Senkel; B Holewa; G U Ryffel
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.